# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 91-100 of 614 results.
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients With Platinum Resistant Ovarian Cancer
Status: Recruiting
Last Changed: Jan 13, 2020
First Received: May 20, 2019
Disease(s): Platinum-resistant Ovarian Cancer
Intervention(s): Niraparib, TSR-042
Locations: Mary Bird Perkins, Covington, Louisiana, United States
Chattanooga Program in Women's Oncology, Chattanooga, Tennessee, United States
Diaphragmatic Resection And Gynecological Ovarian Neoplasm
Status: Recruiting
Last Changed: Jun 01, 2018
First Received: Jun 01, 2018
Disease(s): Ovarian Cancer
Intervention(s): thoracic Drain Tube 24 Fr.
Locations: Fondazione Policlinico Agostino Gemelli, Roma, Rome, Italy
Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Status: Recruiting
Last Changed: Nov 14, 2018
First Received: Jan 10, 2017
Disease(s): Ovarian Neoplasm Epithelial, Hereditary Breast and Ovarian Cancer Syndrome
Locations: Lei Li, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Study of Nutritional Supplement Shakes in People About to Receive Their Debulking Surgery for Ovarian Cancer
Status: Recruiting
Last Changed: Jul 11, 2019
First Received: May 20, 2019
Disease(s): Debulking Surgery for Ovarian Cancer
Intervention(s): nsure Surgery Immunonutrition Shake supplements
Locations: Memorial Sloan Kettering Cancer Center, New York, New York, United States
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Status: Recruiting
Last Changed: Dec 14, 2018
First Received: Oct 09, 2018
Disease(s): Platinum-resistant Recurrent Ovarian Cancer
Intervention(s): olaparib+cediranib combination therapy, durvalumab + olaparib combination therapy, durvalumab + chemotherapy treatment, durvalumab + tremelimumab + chemotherapy treatment
Locations: Seoul National University Hospital, Seoul, Korea, Republic of
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Samsung Medical Center, Seoul, Korea, Republic of
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Status: Recruiting
Last Changed: Jan 09, 2020
First Received: May 10, 2016
Disease(s): Ovarian Cancer
Intervention(s): Pembrolizumab, Carboplatin, Paclitaxel
Locations: Medical College of Wisconsin and Froedtert Hospital, Milwaukee, Wisconsin, United States
SEntine Lymph Node in earLY Ovarian Cancer (SELLY)
Status: Recruiting
Last Changed: Mar 12, 2019
First Received: Jun 20, 2018
Disease(s): Sentinel Lymph Node, Ovarian Cancer Stage I
Intervention(s): Sentinel node detection
Locations: Nuovo Ospedale degli Infermi, Biella, Italy
Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy
Istituto Regina Elena IRCCS, Roma, Italy
Policlinico Universitario Agostino Gemelli, Roma, Italy
Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response
Status: Recruiting
Last Changed: Apr 30, 2019
First Received: Feb 05, 2019
Disease(s): Ovarian Cancer
Intervention(s): collection of blood, urine, tumor and ascite samples
Locations: Centre François BACLESSE, Caen, France
Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study
Status: Recruiting
Last Changed: Aug 28, 2019
First Received: Mar 13, 2018
Disease(s): Ovarian Cancer
Intervention(s): Enzalutamide 40 MG
Locations: Hospital de Mar, Barcelona, Spain
Hospital Reina Sofia, Córdoba, Spain
Hospital Madrid Sanchinarro (CIOCC), Madrid, Spain
Hospital Universitario La Paz, Madrid, Spain
Hospital Son Llatzer, Palma De Mallorca, Spain
... and 4 other locations.
Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.
Status: Not yet recruiting
Last Changed: Mar 16, 2018
First Received: Mar 15, 2018
Disease(s): Recurrent, Platinum-resistant Ovarian Cancer
Intervention(s): Decitabine, Carboplatin, Pegylated Liposomal Doxorubicin, Gemcitabine, Paclitaxel